-

GE HealthCare announces cash dividend for third quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.r.fox@gehealthcare.com

Industry:

GE HealthCare Technologies Inc.

NASDAQ:GEHC
Release Versions
English

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.r.fox@gehealthcare.com

More News From GE HealthCare Technologies Inc.

GE HealthCare announces U.S. FDA 510(k) clearance for View, a next‑generation diagnostic viewer enabling anywhere‑access to radiologists

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that View, the powerful viewer within the Genesis™ Radiology Workspace, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Designed as a fast, diagnostic, zero‑footprint viewer, View serves as the core anchor of the Genesis Radiology Workspace.2 This next‑generation solution aims to transform radiology workflows, unify the user experience, and empower radiologists with greater efficiency and precision. Studies...

GE HealthCare to showcase AI and digital leadership at HIMSS 2026

LAS VEGAS--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will showcase innovations moving healthcare forward at the Health Information and Management Systems Society (HIMSS) Global Health Conference & Exhibition 2026 in Las Vegas from March 9-12, 2026. This year, GE HealthCare will spotlight meaningful technology transforming the way healthcare professionals approach patient care, from imaging operations and fleet management to enterprise solutions, ultrasound, and patient care technologies...

GE HealthCare achieves MRI portfolio milestone with FDA clearances for next-generation SIGNA MRI technology designed to enhance precision imaging and clinical efficiency

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today 510(k) clearance of three new magnetic resonance (MR) innovations with the U.S. Food and Drug Administration (FDA): SIGNA™ Sprint with Freelium™1, a 1.5T sealed magnet MRI system; SIGNA™ Bolt2, an advanced 3T MRI scanner; and SIGNA™ One3, an AI-driven ecosystem of workflow solutions designed to help reduce inefficiencies and support MRI exams from plan to scan and beyond. The new MRI systems and technology combat some of the...
Back to Newsroom